» Articles » PMID: 19100385

Intestinal Ischemia/reperfusion Injury Triggers Activation of Innate Toll-like Receptor 4 and Adaptive Chemokine Programs

Overview
Journal Transplant Proc
Specialty General Surgery
Date 2008 Dec 23
PMID 19100385
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Ischemia/reperfusion injury (IRI) is a major problem in intestinal transplantation. Toll-like receptor 4 (TLR4) has been implicated as a possible link between the innate and adaptive immune systems, however little data exists regarding TLR4 in intestinal IRI. The goal of this study is to evaluate the involvement of TLR4 in intestinal IRI and to assess the effect on T cell related chemokine programs.

Methods: C57BL6 mice underwent 100 minutes of warm intestinal ischemia by SMA clamping. Control WT mice underwent laparotomy without vascular occlusion. Separate survival and analysis groups were performed, and intestinal tissue was harvested at 1 hour, 2 hours, 4 hours, and 24 hours post-reperfusion. Analysis included histology, CD3 immunostaining, myeloperoxidase activity, Western blot, and PCR.

Results: Survival was significantly worse in the IRI group vs control (50% vs. 100%). IRI caused severe histopathological injury including mucosal erosions and villous congestion and hemorrhage. Myeloperoxidase activity increased in a time-dependent manner after IRI (2.71 0.25 at 1 hour, 2.92 0.25 at 2 hours, 4 0.16 at 4 hours, 5.1 0.25 at 24 hours vs 0.47 0.11 controls, P < .05). Protein expression of TLR4 followed by NF-kappaB was increased after IRI. Additionally, mRNA production of IP-10, MIP-2, MCP-1, and RANTES was increased at all time-points, as was mRNA for ICAM-1 and E-selectin.

Conclusion: This study is the first to demonstrate increased expression of TLR4 and NF-kappaB after warm intestinal IRI. This detrimental cascade may be initiated by TLR4 via NF-kappaB signaling pathways, implicating TLR4 as a potential therapeutic target for the prevention of intestinal IRI.

Citing Articles

Immunomodulatory effects of β-defensin 2 on macrophages induced immuno-upregulation and their antitumor function in breast cancer.

Agarwal S, Chauhan A, Singh K, Kumar K, Kaur R, Masih M BMC Immunol. 2022; 23(1):53.

PMID: 36324077 PMC: 9632142. DOI: 10.1186/s12865-022-00527-y.


Qingchang Mixture Prevents the Intestinal Ischemia-reperfusion Injury through TLR4/NF-kB Pathway.

Wang M, Zhu Y, Liu S, Tian Z, Zhu P, Zhang Y Comb Chem High Throughput Screen. 2022; 26(1):49-57.

PMID: 35345995 DOI: 10.2174/1386207325666220328090126.


Molecular Mechanisms Underlying Intestinal Ischemia/Reperfusion Injury: Bioinformatics Analysis and In Vivo Validation.

Chen F, Wang D, Li X, Wang H Med Sci Monit. 2020; 26:e927476.

PMID: 33290384 PMC: 7733309. DOI: 10.12659/MSM.927476.


Gut Microbiota Restricts NETosis in Acute Mesenteric Ischemia-Reperfusion Injury.

Ascher S, Wilms E, Pontarollo G, Formes H, Bayer F, Muller M Arterioscler Thromb Vasc Biol. 2020; 40(9):2279-2292.

PMID: 32611241 PMC: 7484055. DOI: 10.1161/ATVBAHA.120.314491.


Therapeutic targeting of extracellular DNA improves the outcome of intestinal ischemic reperfusion injury in neonatal rats.

Boettcher M, Eschenburg G, Mietzsch S, Jimenez-Alcazar M, Klinke M, Vincent D Sci Rep. 2017; 7(1):15377.

PMID: 29133856 PMC: 5684414. DOI: 10.1038/s41598-017-15807-6.


References
1.
Land W . The role of postischemic reperfusion injury and other nonantigen-dependent inflammatory pathways in transplantation. Transplantation. 2005; 79(5):505-14. DOI: 10.1097/01.tp.0000153160.82975.86. View

2.
Medzhitov R, Janeway Jr C . Innate immunity: impact on the adaptive immune response. Curr Opin Immunol. 1997; 9(1):4-9. DOI: 10.1016/s0952-7915(97)80152-5. View

3.
Farmer D, Shen X, Amersi F, Anselmo D, Ma J, Ke B . CD62 blockade with P-Selectin glycoprotein ligand-immunoglobulin fusion protein reduces ischemia-reperfusion injury after rat intestinal transplantation. Transplantation. 2005; 79(1):44-51. DOI: 10.1097/01.tp.0000146965.64706.e8. View

4.
Muzio M, Polentarutti N, Bosisio D, Prahladan M, Mantovani A . Toll-like receptors: a growing family of immune receptors that are differentially expressed and regulated by different leukocytes. J Leukoc Biol. 2000; 67(4):450-6. DOI: 10.1002/jlb.67.4.450. View

5.
Iwasaki A, Medzhitov R . Toll-like receptor control of the adaptive immune responses. Nat Immunol. 2004; 5(10):987-95. DOI: 10.1038/ni1112. View